Lexicon Pharmaceuticals (NASDAQ:LXRX) Releases Earnings Results

Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03, Zacks reports. The business had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.

Lexicon Pharmaceuticals Stock Down 15.6%

Lexicon Pharmaceuticals stock opened at $0.53 on Thursday. The company has a market capitalization of $192.28 million, a PE ratio of -0.71 and a beta of 1.07. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45. The firm has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.73.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lexicon Pharmaceuticals stock. Invesco Ltd. raised its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 173.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 285,759 shares of the biopharmaceutical company’s stock after buying an additional 181,265 shares during the period. Invesco Ltd. owned approximately 0.08% of Lexicon Pharmaceuticals worth $132,000 as of its most recent SEC filing. 74.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

LXRX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. StockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They issued a “sell” rating for the company. Piper Sandler reduced their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.